Clinical trials: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
- Condition Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
- Funder type Industry (pharma, biotech, devices)
Multiple Sclerosis
A Long-term Extension of Study GNC-401
This Phase II study is a monocenter, long-term extension study of study GNC-401 and will start after individual completion of Week 48 of the GNC-401 study. At entry, all patients will receive active treatment with temelimab.
- Trial name
- NCT05049161
- Testing
- Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg
- Where
- Sweden
- Volunteers
- 33 people
- Sponsor
- GeNeuro Innovation SAS
RRMS
Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece
This is a non interventional, multicenter clinical trial, in adult patients receiving Tecfidera per approved SmPC and routine clinical practice.
- Trial name
- FIDELITY (NCT03101735)
- Testing
- Dimethyl Fumarate (DMF)
- Where
- Greece
- Volunteers
- 455 people
- Sponsor
- Genesis Pharma CNS & Specialty
Multiple Sclerosis
Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis
This is a study to count the number of white blood cells in the cerebrospinal fluid and blood at the beginning and end of treatment with firategrast and at 4 and 12 weeks after stopping firategrast.
- Trial name
- NCT00469378
- Testing
- firategrast
- Where
- 10 sites in Belgium, Czechia and 3 more
- Volunteers
- 46 people
- Sponsor
- GlaxoSmithKline
Relapsing Forms of MS
Exploring Diroximel Fumarate Real-world Experience in Canada and Israel
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice.
- Trial name
- EXPER-CA/IL (NCT04948606)
- Testing
- Diroximel Fumarate
- Where
- 6 sites in Israel
- Volunteers
- 64 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
The primary objective of this study is to demonstrate that the incidence of progressive multifocal Leukoencephalopathy (PML) in natalizumab-treated participants who do not have detectable antibodies to John Cunningham virus (JCV)…
- Trial name
- STRATIFY-2 (NCT01070836)
- Testing
- natalizumab
- Where
- 478 sites in United States, Puerto Rico
- Volunteers
- 35,895 people
- Sponsor
- Biogen
Multiple Sclerosis
NOGO-A in Multiple Sclerosis FTIH
The drug being tested in this study is GSK1223249. The drug works by inhibiting a protein that prevents nerve growth. The trial is expected to involve approximately 36 patients.
- Trial name
- NCT01424423
- Testing
- GSK1223249
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
Relapsing Forms of Multiple Sclerosis
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated with dimethyl fumarate (DMF) after suboptimal…
- Trial name
- RESPOND (NCT01903291)
- Testing
- dimethyl fumarate
- Where
- 62 sites in United States
- Volunteers
- 333 people
- Sponsor
- Biogen
Relapsing Forms of Multiple Sclerosis
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study.
- Trial name
- FUSION (NCT05798520)
- Testing
- BIIB091, DRF
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 127 people
- Sponsor
- Biogen
Multiple Sclerosis
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of…
- Trial name
- FREXALT (NCT06141473)
- Testing
- Frexalimab, Teriflunomide, MRI contrast-enhancing agents
- Where
- 382 sites in United States, Argentina and 39 more
- Volunteers
- 1,655 people
- Sponsor
- Sanofi
Multiple Sclerosis
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to determine the safety and tolerability of ELND002 in patients with relapsing forms of secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01144351
- Testing
- ELND002
- Where
- 20 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Elan Pharmaceuticals
Multiple Sclerosis
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic…
- Trial name
- LEMTRADA-ITP (NCT03784898)
- Testing
- Blood draw for future biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Relapsing-Remitting
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
Significant data from placebo-controlled clinical trials have demonstrated the efficacy of Rebif in relapsing remitting multiple sclerosis (RRMS) with reduction in relapse rate, delay in disability progression, and reduction in…
- Trial name
- COMPARE (NCT01141751)
- Volunteers
- 334 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Safety Study of GNbAC1 in Multiple Sclerosis Patients
The purpose of this study is to assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients.
- Trial name
- NCT01639300
- Testing
- GNbAC1
- Where
- 2 sites in Switzerland
- Volunteers
- 10 people
- Sponsor
- GeNeuro Innovation SAS
Relapsing Multiple Sclerosis
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
This study will evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus booster injection in patients with relapsing MS.
- Trial name
- NCT01199861
- Testing
- Fingolimod, Seasonal influenza vaccine, Tetanus toxoid vaccine
- Where
- 25 sites in Belgium, Canada and 7 more
- Volunteers
- 138 people
- Sponsor
- Novartis
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
It is thought that treating Multiple Sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.
- Trial name
- NCT00203086
- Volunteers
- 30 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Multiple Sclerosis
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
The primary objective of the study is to determine the efficacy of natalizumab (Tysabri, BG00002) in participants with relapsing forms of multiple sclerosis (MS) who have failed Gilenya or BRACET (Betaseron, Rebif, Avonex…
- Trial name
- ESCALATE (NCT02241785)
- Testing
- natalizumab
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Biogen
Relapsing Forms of Multiple Sclerosis
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
In this study, researchers will learn more about the study drugs diroximel fumarate (DRF) and dimethyl fumarate (DMF) in children with MS who may be experiencing relapses.
- Trial name
- VOYAGE (NCT07483632)
- Testing
- Diroximel Fumarate, Dimethyl Fumarate, Fingolimod
- Volunteers
- 185 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
CDP323 Biomarker Study
Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.
- Trial name
- NCT00726648
- Testing
- CDP323
- Where
- 2 sites in United Kingdom
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Relapsing Remitting Multiple Sclerosis
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with relapsing forms of multiple sclerosis.
- Trial name
- NCT01097668
- Testing
- ATX-MS-1467
- Where
- 16 sites in Russia, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Apitope Technology (Bristol) Ltd.
Multiple Sclerosis, Relapsing-Remitting
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot…
- Trial name
- NCT04121221
- Testing
- GA Depot
- Where
- 112 sites in United States, Belarus and 8 more
- Volunteers
- 1,016 people
- Sponsor
- Mapi Pharma Ltd.